Post
newuser1439746
#ModernaQ3财报将揭示疫苗销售趋势
Moderna Q3财报的核心矛盾在于：短期疫苗收入承压与长期管线估值之间的拉锯。市场预期营收约8.9亿美元，同比下滑约12%，新冠疫苗作为基本盘持续退潮，RSV疫苗面对GSK与辉瑞的先发优势难有作为，流感疫苗又错过了2026年美国采购周期，本季贡献微乎其微。但真正值得关注的是公司能否守住全年营收指引与47亿至52亿美元的年底现金目标。若接种季数据未显著恶化，市场或继续将注意力转向肿瘤管线叙事；反之，现金消耗加速将重新引发对mRNA商业化天花板的质疑。
Disclaimer: OKX Orbit content is provided for informational purposes only. Learn more
Replies
No comments yet. Be the first to reply!
Trending crypto
BTC/USDTBitcoin
$72,930.1+0.00%
ETH/USDTEthereum
$2,017.43+0.00%
SOL/USDTSolana
$82.01+0.00%
Today’s market buzz
1#BTC fell below $75,000 before the US October CPI release
2#AI stocks pull back: UBS says position reset, Bank of England warns of crash risk
3#Trump says the possibility of a large-scale strike on Iran is low, oil prices plummet
